Amneal Pharmaceuticals, Inc. - 8-K Filing
Amneal Pharmaceuticals reported Q1 2026 net revenue of $723 million, up 4% from $695 million in Q1 2025, driven by a 23% increase in Specialty segment revenue. GAAP net income was $62 million ($0.19 diluted EPS) compared to $12 million ($0.04 diluted EPS) in the prior year, while adjusted EBITDA rose 19% to $202 million. The company affirmed its full-year 2026 guidance, raising it to net revenue of $3.05–$3.15 billion and adjusted EBITDA of $740–$770 million. (Items: 2.02 of this report)
Tickers: $AMRX